Could a nasal spray stop the next flu pandemic?
NCT ID NCT05397119
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental nasal spray vaccine called BW-1014, designed to protect against pandemic flu. Healthy adults aged 18 to 45 receive two doses of the spray, with or without a nanoemulsion adjuvant, followed by a standard flu shot six months later. Researchers are checking whether the spray is safe and whether it triggers an immune response in the nose and blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an intranasal nanoemulsion-adjuvanted recombinant H5 flu vaccine (BW-1014)
- What this could lead to
- If successful, this could lead to a needle-free nasal spray vaccine that protects against pandemic flu strains.
- What could go wrong
- This is an early Phase 1 trial with only 40 participants, so safety and immune response are still unproven. The vaccine may not generate strong enough protection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA, PANDEMIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Vaccine Development and Global Health, University of Maryland School of Medicine
Baltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.